Search results for "Peni"

showing 10 items of 1692 documents

<em>Centaurea inexpugnabilis</em>, una nueva especie de la sección <em>Acrocentron</em> para la flora ibérica

2017

Se describe una nueva especie para el género Centaurea L. (sect. Acrocentron, Asteraceae): C. inexpugnabilis, sp. nov. Esta planta ha sido localizada al pie de los Mallos de Riglos (Riglos, Huesca) y su distribución se circunscribe por el momento al cuadrante nororiental de la península ibérica. Junto a su descripción y diagnosis, se aporta una lámina y varias tablas con los principales caracteres diagnósticos que la diferencian de las especies más próximas.

0106 biological sciencesgeographygeography.geographical_feature_categorybiology05 social sciences050109 social psychologyPlant ScienceAsteraceaebiology.organism_classification010603 evolutionary biology01 natural sciencesCentaureaPeninsulaBotany0501 psychology and cognitive sciencesCollectanea Botanica
researchProduct

New national and regional bryophyte records, 53

2017

WOS: 000423214200007

0106 biological sciencesgeography.geographical_feature_categorybiologyNational parkSettore BIO/02 - Botanica SistematicaPlant Sciencebiology.organism_classification010603 evolutionary biology01 natural sciencesArchaeologyTierraGeographyPeninsulaBotanyAndreaeaBryophyte[SDE.BE]Environmental Sciences/Biodiversity and EcologyBryophytes Biodiversity National and Regional ListsEcology Evolution Behavior and SystematicsComputingMilieux_MISCELLANEOUS010606 plant biology & botany
researchProduct

Limnology and Aquatic Microbial Ecology of Byers Peninsula: A Main Freshwater Biodiversity Hotspot in Maritime Antarctica

2019

Here we present a comprehensive review of the diversity revealed by research in limnology and microbial ecology conducted in Byers Peninsula (Livingston Island, South Shetland Islands, Antarctica) during the last two decades. The site constitutes one of the largest ice-free areas within the Antarctic Peninsula region. Since it has a high level of environmental protection, it is less human-impacted compared to other sites within the South Shetland archipelago. The main investigations in Byers Peninsula focused on the physical and chemical limnology of the lakes, ponds, rivers, and wetlands, as well as on the structure of their planktonic and benthic microbial communities, and on the function…

0106 biological sciencesvirioplankton010504 meteorology & atmospheric sciencesLimnologyWetlandmaritime antarctica01 natural sciencesPeninsulabyers peninsulalcsh:QH301-705.50105 earth and related environmental sciencesNature and Landscape ConservationprotistsShetlandFunctional ecologygeographygeography.geographical_feature_categoryEcologyEcologybacterioplankton010604 marine biology & hydrobiologyEcological Modelingmicrobial matsPlanktonAgricultural and Biological Sciences (miscellaneous)lcsh:Biology (General)Productivity (ecology)Benthic zonenext-generation sequencingDiversity
researchProduct

Anti-Listeria activity of lactic acid bacteria in two traditional Sicilian cheeses

2017

<em>Listeria monocytogenes</em> is a pathogen frequently found in dairy products, and its growth is difficult to control. Bacteriocinlike inhibitory substances (BLIS), produced by lactic acid bacteria (LAB), having proven <em>in vitro</em> anti-<em>Listeria</em> activity, could provide an innovative approach to control <em>L. monocytogenes</em>; however, this application needs to be evaluated <em>in vivo</em>. In this study, twenty LAB strains isolated from different Sicilian dairy environments were tested for control of growth of <em>L. monocytogenes</em> in three different experimental trials. First, raw and UHT milk …

0301 basic medicine030106 microbiologyBacteriocin-like inhibitory substances (BLIS)BiologyBLISmedicine.disease_causeArticleTraditional Sicilian cheesesMicrobiology03 medical and health scienceschemistry.chemical_compoundListeria monocytogenesmedicineSettore AGR/18 - Nutrizione E Alimentazione AnimaleRaw MilkIn vivo applicationsFood sciencePathogenlcsh:TP368-456InoculationRipeningbiology.organism_classificationListeria monocytogenesLactic acidlcsh:Food processing and manufactureMilkchemistryListeriaBacteriaSettore AGR/16 - Microbiologia AgrariaFood ScienceItalian Journal of Food Safety
researchProduct

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

2017

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, …

0301 basic medicine030204 cardiovascular system & hematologylaw.invention0302 clinical medicinec-reactive proteinRandomized controlled triallawCardiovascular Diseasemiddle ageddouble-blind methodantibodiesMyocardial infarctionhumansStrokeinterleukin-1betabiologyAntibodies MonoclonaldrugGeneral MedicineLipidAged; anti-inflammatory agents; antibodies; monoclonal; antibodies; monoclonal; humanized; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship; drug; double-blind method; female; humans; incidence; infections; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; strokestrokeAnti-Inflammatory AgentagedEditorialfemalemyocardial infarctionAtherosclerosiMonoclonalsecondary preventionHumanmedicine.drugmedicine.medical_specialtymonoclonalNeutropeniaAntibodies Monoclonal HumanizedInfectionsPlaceboaged; anti-inflammatory agents; antibodies monoclonal; atherosclerosis; c-reactive protein; cardiovascular diseases; dose-response relationship drug; double-blind method; female; humans; incidence; infection; interleukin-1beta; lipids; male; middle aged; myocardial infarction; neutropenia; secondary prevention; stroke; medicine (all)anti-inflammatory agentsdose-response relationshiplipids03 medical and health sciencesmaleInternal medicinemedicineneutropeniamedicine (all)Dose-Response Relationship Drugbusiness.industryAntiinflammatory Therapy Canakinumab for Atherosclerotic DiseaseC-reactive proteinmedicine.diseaseinfectioncardiovascular diseasesSurgeryCanakinumab030104 developmental biologyincidencebiology.proteinatherosclerosisbusinessNew England journal of medicine
researchProduct

Altered chemotactic response to CXCL12 in patients carrying GATA2 mutations.

2015

Abstract GATA2 deficiency—formerly described as MonoMAC syndrome; dendritic cells, monocytes, B cells, and natural killer cell deficiency; familial myelodysplastic syndrome/acute myeloid leukemia; or Emberger syndrome—encompasses a range of hematologic and nonhematologic anomalies, mainly characterized by monocytopenia, B lymphopenia, natural killer cell cytopenia, neutropenia, immunodeficiency, and a high risk of developing acute myeloid leukemia. Herein, we present 7 patients with GATA2 deficiency recruited into the French Severe Chronic Neutropenia Registry, which enrolls patients with all kinds of congenital neutropenia. We performed extended immunophenotyping of their whole blood lymph…

0301 basic medicineAdultMaleReceptors CXCR4AdolescentLymphocyteT-LymphocytesImmunologyMonocytopeniaBiologyNatural killer cell03 medical and health sciencesYoung AdultImmunophenotypinghemic and lymphatic diseasesmedicineImmunology and AllergyHumansLymphocyte CountCongenital NeutropeniaChildAgedCytopeniaB-LymphocytesGATA2 DeficiencyTraditional medicineChemotaxisCell MembraneMyeloid leukemiaCell Biologymedicine.diseaseCD56 AntigenChemokine CXCL12GATA2 Transcription FactorKiller Cells Natural030104 developmental biologymedicine.anatomical_structureImmunologyMutationFemaleJournal of leukocyte biology
researchProduct

Valorization of indigenous dairy cattle breed through salami production

2016

The aim of the research was to produce salami manufactured with meat of three different commercial categories of bovine breed: cow on retirement, beef and young bull. A total of six experimental productions, at small-scale plant, were carried out with and without starter culture inoculums. The evolution of physico-chemical parameters in all trials followed the trend already registered for other fermented meat products. Several LAB species were found during process with different levels of species diversity and frequency of isolation among inoculated (mainly Pediococcus pentosaceus and Staphylococcus xylosus) and uninoculated (mainly Enterococcus devriesei, Lactobacillus curvatus and Lactoba…

0301 basic medicineAdultMaleSettore AGR/19 - Zootecnica SpecialeMeatCinisara breed; Lactic acid bacteria; Meat fermentation; Salami; Starter culture; Adult; Animals; Bacteria; Cattle; Female; Food Handling; Humans; Male; Meat; Meat Products; Breeding; Fermentation; Food Microbiology; Food ScienceFood Handling030106 microbiologySalamiBreedingSensory analysis03 medical and health sciencesSettore AGR/17 - Zootecnica Generale E Miglioramento GeneticoStarterLactic acid bacteriaAnimalsHumansFood scienceDairy cattleMeat ProductbiologyBacteriaInoculationMeat fermentationAnimal0402 animal and dairy scienceStaphylococcus xylosusfood and beveragesRipening04 agricultural and veterinary sciencesSettore AGR/15 - Scienze E Tecnologie Alimentaribiology.organism_classification040201 dairy & animal scienceBreedLactobacillus sakeiMeat ProductsStarter cultureFermentationFood MicrobiologyCattleFemaleCinisara breedHumanFood ScienceSettore AGR/16 - Microbiologia Agraria
researchProduct

Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodyspla…

2017

This is an observational-retrospective study comparing the real-world outcomes associated with posaconazole vs. itraconazole as prophylaxis treatments. Two hundred and ninety-three patient admissions attributable to 174 patients were included in the study. Patients were treated with itraconazole (n = 114 admissions; 39%) or posaconazole (n = 179; 61%). Antifungal prophylaxis failure (APF) due to treatment-related adverse events (in 34 out of 293 patient admissions; 11.6%) was more frequent in the posaconazole group (6.1% vs. 15.1%; P = 0.024). There were 9 patient admissions for episodes of APF due to probable/proven breakthrough fungal infection (primary endpoint): 6 and 3 in the itraconaz…

0301 basic medicineAdultMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsDrug-Related Side Effects and Adverse ReactionsItraconazole030106 microbiologyDermatologyNeutropenia03 medical and health sciencesInternal medicinemedicineClinical endpointHumansIn patientTreatment FailureAdverse effectAgedRetrospective StudiesInvasive Pulmonary Aspergillosisbusiness.industryMyelodysplastic syndromesGeneral MedicineMiddle AgedTriazolesmedicine.diseaseSurgeryClinical trialLeukemia Myeloid AcuteInfectious DiseasesMyelodysplastic SyndromesFemalePre-Exposure ProphylaxisItraconazolebusinessInvasive Fungal Infectionsmedicine.drugMycoses
researchProduct

Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia

2018

IF 7.607; International audience; Innate lymphoid cells (ILCs) have been characterized as innate immune cells capable to modulate the immune response in the mucosae. Human ILCs have been rarely described in secondary lymphoid organs except in tonsils. Moreover, their function and phenotype in human secondary lymphoid organs during autoimmune diseases have never been studied. We took advantage of splenectomy as a treatment of immune thrombocytopenia (ITP) to describe and compare splenic ILC from 18 ITP patients to 11 controls. We first confirmed that ILC3 represented the most abundant ILC subset in human non-inflamed spleens, accounting for 90% of total ILC, and that they were mostly constit…

0301 basic medicineAdultMalemedicine.medical_treatmentImmunologySplenectomyGene ExpressionSpleenInnate lymphoid cells[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInterferon-gamma0302 clinical medicineImmune systemhemic and lymphatic diseasesmedicineImmunology and AllergyHumansLymphocyte CountLymphocytesskin and connective tissue diseasesAutoimmune diseasePurpura Thrombocytopenic IdiopathicInnate immune systemNatural Cytotoxicity Triggering Receptor 2business.industryMacrophagesInnate lymphoid cellInterleukin-2 Receptor alpha SubunitGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationMiddle Agedmedicine.diseasePathophysiologyImmunity Innate3. Good healthImmune thrombocytopenia030104 developmental biologymedicine.anatomical_structureLymphatic systemCase-Control StudiesImmunologySplenectomyFemalebusinessSpleen030215 immunology
researchProduct

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer…

2016

Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. Here, we report 5-year progression-free survival, disease-free survival, and safety. Methods In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-positive breast cancer were randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do…

0301 basic medicineAdultmedicine.medical_specialtyTime FactorsAdolescentReceptor ErbB-2PopulationAntibodies Monoclonal HumanizedGastroenterologyGroup B03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle AgedTrastuzumabmedicine.diseasePrognosisNeoadjuvant TherapySurgerySurvival Rate030104 developmental biologyOncologyDocetaxelTolerabilityChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleInflammatory Breast NeoplasmsPertuzumabNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drugEpirubicinFollow-Up StudiesThe Lancet. Oncology
researchProduct